Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ambulatory male subjects ≥ 55 years to ≤ 90 years of age~* Must have a BMD T score ≤ -2.50 at the spine or hip, or BMD T score ≤ -1.50 at the spine or hip and a history of fragility nonvertebral fracture or vertebral fracture.~Exclusion Criteria:~* A BMD T score ≤ -3.50 at the hip,~* History of hip fracture~* Severe metabolic bone diseases~* Significant laboratory abnormalities~* Recent treatment with agents affecting bone metabolism

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Romosozumab (Type: EXPERIMENTAL): Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injections once a month for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).